Calliditas Therapeutics Reports Data From Phase 2 Study Of Setanaxib In Combination With Pembrolizumab For Head And Neck Cancer
Calliditas Therapeutics Reports Data From Phase 2 Study Of Setanaxib In Combination With Pembrolizumab For Head And Neck Cancer
Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN). The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in overall survival (OS), with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib.
Calliditas Therapeutics AB（納斯達克股票代碼：CALT）（納斯達克斯德哥爾摩股票代碼：CALTX）（“Calliditas”）今天公佈了其主要氮氧化物酶抑制劑setanaxib與pembrolizumab聯合治療頭頸部鱗狀細胞癌（SCCHN）患者的概念驗證2期試驗的數據。分析顯示，無進展存活率（PFS）和總存活率（OS）具有統計學上的顯著改善，腫瘤生物學的統計學顯著變化與setanaxib的作用機制一致。
譯文內容由第三人軟體翻譯。